SCHEMBL1741357

SCHEMBL1741357

CCCCCCC(NC(C)=O)C(C)=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.58
SIRT1 Q96EB6 1/20 0.58
PLA2G2C Q5R387 3/20 0.47
TLR2 O60603 2/20 0.46
PLA2G2A P14555 1/20 0.45
NOD1 Q9Y239 1/20 0.45
GPR84 Q9NQS5 5/20 0.44
FFAR1 O14842 1/20 0.44
ZDHHC7 Q9NXF8 1/20 0.43
MAPT P10636 1/20 0.42
LCK P06239 1/20 0.42
PPARD Q03181 1/20 0.42
ZDHHC20 Q5W0Z9 1/20 0.42
ZDHHC2 Q9UIJ5 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
MEN1 O00255 1/20 0.41
FAAH O00519 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20435333 0.98 SIRT6 (0.55) SIRT6SIRT1PLA2G2CTLR2PLA2G2A
SCHEMBL14978808 0.98 SIRT6 (0.55) SIRT6SIRT1PLA2G2CTLR2PLA2G2A
SCHEMBL13525107 0.92 SIRT6 (0.49) SIRT6SIRT1PLA2G2CTLR2NOD1
SCHEMBL10603414 0.86 NOD1 (0.60) SIRT6SIRT1NOD1GPR84FFAR1
SCHEMBL21801849 0.86 NOD1 (0.60) SIRT6SIRT1NOD1GPR84FFAR1
SCHEMBL10600983 0.86 NOD1 (0.60) SIRT6SIRT1NOD1GPR84FFAR1
SCHEMBL4609045 0.86 NOD1 (0.60) SIRT6SIRT1NOD1GPR84FFAR1
SCHEMBL10599643 0.86 NOD1 (0.60) SIRT6SIRT1NOD1GPR84FFAR1
SCHEMBL10599977 0.86 NOD1 (0.60) SIRT6SIRT1NOD1GPR84FFAR1
SCHEMBL10603409 0.86 NOD1 (0.60) SIRT6SIRT1NOD1GPR84FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043637-B2 Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing ILLUMINA CAMBRIDGE LIMITED (GB) 2024-07-23 US disclosed
US-20230304086-A1 LABELED AVIDIN AND METHODS FOR SEQUENCING ILLUMINA CAMBRIDGE LIMITED (GB) 2023-09-28 US disclosed
US-20120202287-A1 Stem Cell Culture Methods ITI SCOTLAND LIMITED (GB) 2012-08-09 US disclosed
EP-2389436-A2 STEM CELL CULTURE METHODS ITI Scotland Limited (GB) 2011-11-30 EP disclosed
US-20110257911-A1 SYSTEMS AND METHODS FOR DETECTING CHANGES IN ENERGY USAGE IN A BUILDING JOHNSON CONTROLS TECHNOLOGY COMPANY 2011-10-20 US disclosed
WO-2010084300-A2 STEM CELL CULTURE METHODS ITI SCOTLAND LIMITED (GB) 2010-07-29 WO disclosed
EP-0009154-B1 COMPLEXES OF 9-HYDROXYALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITIONS CONTAINING THE COMPLEXES AS ACTIVE INGREDIENTS Newport Pharmaceuticals International, Inc. (US) 1982-12-08 EP disclosed
EP-0009155-B1 9-HYDROXYALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITION CONTAINING THE 9-HYDROXYALKYL-PURINES AS ACTIVE INGREDIENTS Newport Pharmaceuticals International, Inc. (US) 1982-11-17 EP disclosed
US-4221794-A Method of imparting immunomodulating and antiviral activity NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) 1980-09-09 US disclosed
US-4221909-A P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1980-09-09 US disclosed
US-4221910-A IMMUNOPOTENTIATORS, VIRICIDES, ANTILEUKEMIA AGENTS NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) 1980-09-09 US disclosed
EP-0009155-A1 9-Hydroxyalkyl-purines, processes for preparing them and therapeutical composition containing the 9-hydroxyalkyl-purines as active ingredients Newport Pharmaceuticals International, Inc. (US) 1980-04-02 EP disclosed
EP-0009154-A1 Complexes of 9-hydroxyalkyl-purines, processes for preparing them and therapeutical compositions containing the complexes as active ingredients Newport Pharmaceuticals International, Inc. (US) 1980-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043637-B2 Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing BLVRB, BCDIN3D, FOSB SIRT6 2892/4885SIRT1 3455/4885PLA2G2C 4457/4885
US-20230304086-A1 LABELED AVIDIN AND METHODS FOR SEQUENCING ANXA6, ANXA3, BCDIN3D SIRT6 3723/4885SIRT1 4729/4885PLA2G2C 3693/4885
US-20120202287-A1 Stem Cell Culture Methods KIT, SOX18, MCL1 SIRT6 2660/4885SIRT1 1015/4885PLA2G2C 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.